Aerie Pharmaceuticals Logo

News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

OIS European Innovation Showcase

Corporate Presentation – June

OIS Dry Eye Innovation Showcase Presentation

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 20, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 15, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Frank Estrada, Ed.D., as Director, Salesforce Training
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 21, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference – UPDATED RELEASE
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 21, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
TOP